bluebird bio, Inc.: restructuring charge — bluebird bio cuts workforce 25%, targets 20% opex reduction and cash flow break-even in H2 2025

bluebird bio, Inc.

Restructuring reduces headcount by ~25% and cash operating expenses by ~20% when fully realized in Q3 2025.
One-time cash charges of ~$3.7M for severance; stock-based compensation of $0.3M-$0.5M; most recorded in Q3 2024.
Cash flow break-even target in H2 2025 requires ~40 drug product deliveries per quarter and additional capital.
Year-to-date 41 patient starts; expects ~40 patient starts in Q4 2024 across three approved gene therapies.
Restructuring substantially complete by Q1 2025; savings fully realized Q3 2025.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

bluebird bio, Inc. announced a restructuring with charges of approximately $3.7 million in cash expenditures for severance and employee termination-related costs (approximately 25% of its headcount).

Type: restructuring
Charge: approximately $3.7 million in cash expenditures for severance and employee termination-related costs
Headcount: approximately 25% of its headcount

Exact text from the filing

The Company’s board of directors approved the Restructuring on September 23, 2024, following a comprehensive review of the Company’s operations. The Restructuring includes a reduction of the Company’s workforce by approximately 25% of its headcount. As a result of the Restructuring, the Company estimates that it will incur aggregate charges of approximately $3.7 million in cash expenditures for severance and employee termination-related costs to be paid out over multiple weeks through the end of the fiscal year ending December 31, 2024, as well as approximately $0.3 million - $0.5 million in stock-based compensation expense.

View on SEC.gov

Browse all restructurings & charges →

Source: SEC EDGAR

accession 0001293971-24-000046

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.